Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

12 Months Ended

Jul. 31, 2013

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2013	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	55,889			—			—			—		$	55,889
Product revenues		—		$	32,526			—			—			32,526
Royalty and license fee income		—			5,292			—			—			5,292
Total revenues		55,889			37,818			—			—			93,707

Operating expenses:
Cost of clinical laboratory services		38,251			—			—			—			38,251
Cost of product revenues		—			16,584			—			—			16,584
Research and development		294			2,356		$	1,239			—			3,889
Selling, general and administrative		19,942			15,511			—		$	8,201			43,654
Provision for uncollectible accounts receivable		4,232			264			—			—			4,496
Legal		316			57			—			5,440			5,813
Total operating expenses		63,035			34,772			1,239			13,641			112,687


Operating income (loss)		(7,146	)		3,046			(1,239	)		(13,641	)		(18,980	)

Other income (expense)
Interest		(46	)		13			—			(21	)		(54	)
Other		49			(71	)		—			27			5
Foreign exchange gain		—			80			—			—			80

(Loss) income before income taxes	$	(7,143	)	$	3,066		$	(1,239	)	$	(13,635	)	$	(18,949	)

Depreciation and amortization included above	$	1,377		$	3,102		$	22		$	104		$	4,605

Share-based compensation included in above:
Cost of clinical laboratory services	$	9		$	1			—			—		$	10
Research and development		—			2			—			—			2
Selling, general and administrative		36			10			—		$	487			533
Total	$	45		$	13			—		$	487		$	545

Capital expenditures	$	757		$	231			—			—		$	988

Year ended July 31, 2012	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	59,403			—			—			—		$	59,403
Product revenues		—		$	37,722			—			—			37,722
Royalty and license fee income		—			5,958			—			—			5,958
Total revenues		59,403			43,680			—			—			103,083

Operating expenses:
Cost of clinical laboratory services		36,305			—			—			—			36,305
Cost of product revenues		—			19,668			—			—			19,668
Research and development		299			4,308		$	1,686			—			6,293
Selling, general and administrative		20,856			18,305			—		$	8,767			47,928
Provision for uncollectible accounts receivable		4,987			117			—			—			5,104
Legal		262			536			—			2,926			3,724
Impairment charges		—			24,540			—			—			24,540
Total operating expenses		62,709			67,474			1,686			11,693			143,562


Operating loss		(3,306	)		(23,794	)		(1,686	)		(11,693	)		(40,479	)

Other income (expense)
Interest		(5	)		23			—			3			21
Other		28			27			—			22			77
Foreign exchange loss		—			(540	)		—			—			(540	)

Loss before income taxes	$	(3,283	)	$	(24,284	)	$	(1,686	)	$	(11,668	)	$	(40,921	)

Depreciation and amortization included above	$	1,092		$	3,217		$	43		$	125		$	4,477

Share-based compensation included in above:
Cost of clinical laboratory services	$	10						—			—		$	10
Research and development		—		$	4			—			—			4
Selling, general and administrative		49			59			—		$	597			705
Total	$	59		$	63			—		$	597		$	719

Capital expenditures	$	921		$	443			—			—		$	1,364

Year ended July 31, 2011	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	52,762						—			—		$	52,762
Product revenues		—		$	41,830			—			—			41,830
Royalty and license fee income		—			7,437			—			—			7,437
Total revenues		52,762			49,267			—			—			102,029

Operating expenses:
Cost of clinical laboratory services		31,682			—			—			—			31,682
Cost of product revenues		—			22,137			—			—			22,137
Research and development		—			5,784		$	2,022			—			7,806
Selling, general and administrative		18,426			17,855			—		$	8,910			45,191
Provision for uncollectible accounts receivable		4,415			16			—			—			4,431
Legal		387			726			—			2,597			3,710
Total operating expenses		54,910			46,518			2,022			11,507			114,957

Operating (loss) income		(2,148	)		2,749			(2,022	)		(11,507	)		(12,928	)

Other income (expense)
Interest		(5	)		2			—			14			11
Other		30			(3	)		—			18			45
Foreign exchange gain		—			49			—			—			49
(Loss) income before income taxes	$	(2,123	)	$	2,797		$	(2,022	)	$	(11,475	)	$	(12,823	)

Depreciation and amortization included above	$	1,012		$	3,282		$	47		$	128		$	4,469

Share-based compensation included in above:
Cost of clinical laboratory services	$	10			—		$	—			—		$	10
Research and development		—		$	14			—			—			14
Selling, general and administrative and legal		61			84			—		$	880			1,025
Total		71			98		$	—		$	880		$	1,049

Capital expenditures	$	834		$	389			—			—		$	1,223

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Geographic financial information is as follows:

Net sales to unaffiliated customers:	2013		2012		2011
United States	$	80,559	$	87,776	$	85,691
Switzerland		5,499		6,802		8,508
United Kingdom		2,324		2,728		2,825
Other international countries		5,325		5,777		5,005
Total	$	93,707	$	103,083	$	102,029

Long-lived assets at July 31,		2013		2012		2011
United States	$	23,136	$	25,081	$	44,028
Switzerland		1,984		2,223		8,958
United Kingdom		491		618		2,857
Other international countries		401		426		1,850
Total	$	26,012	$	28,348	$	57,693

Schedule of Segment Revenue By Geographical [Table Text Block]

The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries:

	2013		2012		2011
United States	$	24,669	$	28,372	$	32,928
Foreign countries		13,149		15,308		16,339
	$	37,818	$	43,680	$	49,267

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details